Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 14/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 12/20 | 0.57 |
| ▸ | MAP2K4 | P45985 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | MAPKAPK3 | Q16644 | 2/20 | 0.53 |
| ▸ | MAPK6 | Q16659 | 2/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | FADS1 | O60427 | 1/20 | 0.50 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.48 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14528922 | 0.88 | CCR2 (0.56) | CCR2KCNH2MAP2K4MAPK1MAPKAPK3 | |
| SCHEMBL2992022 | 0.83 | CCR2 (0.60) | CCR2KCNH2MAP2K4MAPK1MAPKAPK3 | |
| SCHEMBL2634461 | 0.81 | CCR2 (0.69) | CCR2KCNH2CRHR1 | |
| SCHEMBL6476809 | 0.77 | GSK3B (0.82) | GSK3B | |
| SCHEMBL14487354 | 0.77 | MAP2K4 (0.56) | CCR2KCNH2MAP2K4MAPK1MAPKAPK3 | |
| SCHEMBL628596 | 0.76 | FADS1 (0.58) | CCR2KCNH2MAP2K4MAPK1MAPKAPK3 | |
| SCHEMBL11703556 | 0.76 | FADS1 (0.58) | CCR2KCNH2MAP2K4MAPK1MAPKAPK3 | |
| SCHEMBL11969786 | 0.75 | GSK3B (0.49) | CCR2KCNH2MAP2K4MAPK1MAPKAPK3 | |
| SCHEMBL11748390 | 0.75 | FADS1 (0.54) | CCR2KCNH2MAP2K4MAPK1MAPKAPK3 | |
| SCHEMBL28206086 | 0.75 | MAP2K4 (0.64) | MAP2K4MAPK1MAPKAPK3MAPK6GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2580208-B1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-06 | — | — | EP | disclosed |
| US-8436023-B2 | Cyclohexyl-azetidinyl antagonists of CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-05-07 | — | — | US | disclosed |
| EP-2580208-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | Janssen Pharmaceutica, N.V. (BE) | 2013-04-17 | — | — | EP | disclosed |
| US-20120214807-A1 | COMPOUNDS USEFUL AS ANTAGONISTS OF CCR2 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20110306592-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-12-15 | — | — | US | disclosed |
| WO-2011156554-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-15 | — | — | WO | disclosed |
| US-8067457-B2 | Compounds useful as antagonists of CCR2 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20090197884-A1 | Compounds Useful as Antagonists of CCR2 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| US-7378409-B2 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| EP-1656138-A4 | SUBSTITUTED CYCLOALKYAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2007-04-18 | — | — | EP | disclosed |
| US-7087604-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-08 | — | — | US | disclosed |
| EP-1656138-A2 | SUBSTITUTED CYCLOALKYAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2006-05-17 | — | — | EP | disclosed |
| WO-2005020899-A2 | SUBSTITUTED CYCLOALKYAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214807-A1 | COMPOUNDS USEFUL AS ANTAGONISTS OF CCR2 | CCR2, CCR1, CXCR3 | CCR2 1/4885KCNH2 2318/4885MAP2K4 1461/4885 |
| US-20090197884-A1 | Compounds Useful as Antagonists of CCR2 | CCR2, CCR1, CXCR3 | CCR2 1/4885KCNH2 2318/4885MAP2K4 1461/4885 |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | CCR2 3/4885KCNH2 1662/4885MAP2K4 3474/4885 |
| US-20110306592-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | CCR2, CCR1, CCR5 | CCR2 1/4885KCNH2 1296/4885MAP2K4 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.